B-cell acute lymphoblastic leukemia · 13 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
HAM and Imatinib Variant #01 | BCR::ABL1 | R 29 235 | 4d | — | — | — | — | — |
Dasatinib and Blinatumomab Variant #01 | BCR::ABL1 | R 27 087 | 42d | — | — | — | — | — |
Nilotinib-based consolidation Variant #01 | BCR::ABL1 | R 16 904 | — | — | — | — | — | — |
International ALL Trial consolidation Variant #01 | — | R 15 419 | 56d | — | — | — | — | — |
Pediatric-like GRAALL consolidation Variant #01 | — | R 7 690 | — | — | — | — | — | — |
Etoposide and TBI, then allo HSCT Variant #03 | BCR::ABL1 | R 6 278 | — | — | — | — | — | — |
Etoposide and TBI, then allo HSCT Variant #03 | — | R 6 278 | — | — | — | — | — | — |
AALL0232 consolidation Variant #01 | — | R 5 050 | 50d | — | — | — | — | — |
Cyclophosphamide and TBI, then allo HSCT Variant #01 | — | R 1 176 | — | — | — | — | — | — |
Cyclophosphamide and TBI, then allo HSCT Variant #01 | BCR::ABL1 | R 1 176 | — | — | — | — | — | — |
Linker regimen (consolidation) N/A - secondary systemic drug | — | R 431 | — | — | — | — | — | — |
Blinatumomab monotherapy N/A - secondary systemic drug | — | R 18 | 28d | — | ~7.7 mo | — | — | 2 |
Mercaptopurine, Methotrexate, Vincristine N/A - intrathecal component | — | R 18 | — | — | — | — | — | — |
13 of 13 regimens shown